Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 OptiNoseAtossa TherapeuticsConcert PharmaceuticalsMedicenna TherapeuticsIterum Therapeutics
SymbolNASDAQ:OPTNNASDAQ:ATOSNASDAQ:CNCENASDAQ:MDNANASDAQ:ITRM
Price Information
Current Price$3.51$1.63$4.41$3.97$1.10
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.21.70.71.3
Analysis Score3.33.53.53.53.3
Community Score2.42.52.70.02.4
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.00.0
Earnings & Valuation Score0.60.00.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$18.00$7.50$20.50$10.00$3.25
% Upside from Price Target412.82% upside360.12% upside364.85% upside151.89% upside195.45% upside
Trade Information
Market Cap$185.84 million$196.94 million$141.89 million$210.23 million$194.13 million
Beta1.032.340.771.391.49
Average Volume440,04321,996,809484,403211,38625,012,971
Sales & Book Value
Annual Revenue$34.63 millionN/A$1.08 millionN/A$40,000.00
Price / Sales5.37N/A131.38N/A4,853.15
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.48 per share$1.37 per share$4.26 per share$0.77 per share($1.88) per share
Price / Book2.37N/A1.04N/A-0.59
Profitability
Net Income$-110,050,000.00$-17,240,000.00$-78,170,000.00$-6,220,000.00$-103,130,000.00
EPS($2.63)N/A($3.29)($0.19)($7.10)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-230.14%N/A-921.38%N/AN/A
Return on Equity (ROE)-294.64%-130.58%-55.20%-40.19%N/A
Return on Assets (ROA)-59.29%-108.14%-44.83%-37.66%-179.51%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio3.79%N/AN/AN/AN/A
Current Ratio3.98%7.23%18.51%26.75%0.30%
Quick Ratio3.76%7.23%18.51%26.75%0.30%
Ownership Information
Institutional Ownership Percentage62.93%6.87%69.68%3.90%10.14%
Insider Ownership Percentage38.00%33.21%10.10%N/A22.10%
Miscellaneous
Employees20447177
Shares Outstanding52.95 million120.82 million32.17 million52.96 million176.48 million
Next Earnings Date5/6/2021 (Estimated)5/12/2021 (Estimated)4/29/2021 (Estimated)5/21/2021 (Estimated)5/13/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
For Iterum Therapeutics plc [ITRM], Analyst sees a rise to $2.50. What next?For Iterum Therapeutics plc [ITRM], Analyst sees a rise to $2.50. What next?
dbtnews.com - April 13 at 8:14 PM
Iterum Therapeutics plc (NASDAQ:ITRM) Is An Exciting StockIterum Therapeutics plc (NASDAQ:ITRM) Is An Exciting Stock
stocksregister.com - April 12 at 6:15 PM
Shares of Iterum Therapeutics plc (NASDAQ:ITRM) lost -8.33% in a month.Shares of Iterum Therapeutics plc (NASDAQ:ITRM) lost -8.33% in a month.
marketingsentinel.com - April 12 at 8:14 AM
BRIEF-Iterum Therapeutics Says FDA Needs More Time To Review Materials Provided In Support Of NDABRIEF-Iterum Therapeutics Says FDA Needs More Time To Review Materials Provided In Support Of NDA
msn.com - April 10 at 7:06 PM
Why Iterum (ITRM) Stock Is Plunging Today?Why Iterum (ITRM) Stock Is Plunging Today?
benzinga.com - April 9 at 11:17 AM
Iterum Therapeutics to Present at the 20th Annual Needham Virtual Healthcare ConferenceIterum Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 6 at 9:28 AM
Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Rises By 45.2%Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Rises By 45.2%
americanbankingnews.com - April 1 at 8:28 AM
Iterum Therapeutics plc (NASDAQ:ITRM) is up 43.58 percent year-to-date, but analysts anticipate a price rallyIterum Therapeutics plc (NASDAQ:ITRM) is up 43.58 percent year-to-date, but analysts anticipate a price rally
stocksregister.com - March 26 at 3:11 PM
12-month price target for Iterum Therapeutics plc (NASDAQ:ITRM) now sits at $2.512-month price target for Iterum Therapeutics plc (NASDAQ:ITRM) now sits at $2.5
marketingsentinel.com - March 26 at 10:11 AM
Iterum Therapeutics Stock Looks Like a High-Risk Name HereIterum Therapeutics Stock Looks Like a High-Risk Name Here
feedproxy.google.com - March 22 at 9:54 AM
Iterum Therapeutics’ Science Won’t Prevent Its VolatilityIterum Therapeutics’ Science Won’t Prevent Its Volatility
feedproxy.google.com - March 18 at 6:12 AM
Iterum Therapeutics Appoints Beth P. Hecht to Board of DirectorsIterum Therapeutics Appoints Beth P. Hecht to Board of Directors
finance.yahoo.com - March 16 at 10:27 AM
ITRM Stock Price Increased 1.94% After Hours: Why It HappenedITRM Stock Price Increased 1.94% After Hours: Why It Happened
pulse2.com - March 14 at 12:49 PM
Iterum Therapeutics plc (ITRM) CEO Corey Fishman on Q4 2020 Results - Earnings Call TranscriptIterum Therapeutics plc (ITRM) CEO Corey Fishman on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 14 at 7:48 AM
ITRM Stock Price Increases Over 5% Pre-Market: Why It HappenedITRM Stock Price Increases Over 5% Pre-Market: Why It Happened
pulse2.com - March 12 at 10:05 PM
Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial ResultsIterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 12 at 10:05 PM
Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host ...Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host ...
apnews.com - March 5 at 7:01 PM
Unfavorable Earnings Profile Doesn’t Bode Well for Iterum Therapeutics StockUnfavorable Earnings Profile Doesn’t Bode Well for Iterum Therapeutics Stock
feedproxy.google.com - March 2 at 12:21 PM
Iterum Therapeutics to Present in Upcoming Investor ConferencesIterum Therapeutics to Present in Upcoming Investor Conferences
finance.yahoo.com - February 19 at 8:09 PM
Iterum Therapeutics plc Announces Exercise of Underwriters Option to Purchase Additional Ordinary SharesIterum Therapeutics plc Announces Exercise of Underwriter's Option to Purchase Additional Ordinary Shares
marketwatch.com - February 11 at 9:06 AM
ITRM Stock Price Increases Over 15% Pre-Market: Why It HappenedITRM Stock Price Increases Over 15% Pre-Market: Why It Happened
pulse2.com - February 11 at 9:06 AM
Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares ...Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares ...
apnews.com - February 11 at 4:05 AM
Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional ...Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional ...
apnews.com - February 11 at 4:05 AM
Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary SharesIterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares
finance.yahoo.com - February 10 at 10:20 PM
Iterum Therapeutics Presses Capital Raise Button To Support Potential Sulopenem Launch ActivitiesIterum Therapeutics Presses Capital Raise Button To Support Potential Sulopenem Launch Activities
feeds.benzinga.com - February 10 at 6:47 AM
DateCompanyBrokerageAction
7/16/2020OptiNosePiper SandlerReiterated Rating
7/16/2020OptiNoseRoyal Bank of CanadaReiterated Rating
3/5/2020OptiNoseCantor FitzgeraldLower Price Target
12/18/2019OptiNoseCowenInitiated Coverage
8/13/2019OptiNoseBMO Capital MarketsLower Price Target
4/23/2019OptiNosePiper Jaffray CompaniesSet Price Target
9/18/2020Atossa TherapeuticsMaxim GroupReiterated Rating
9/17/2020Atossa TherapeuticsAscendiant Capital MarketsInitiated Coverage
5/15/2018Atossa TherapeuticsNoble FinancialSet Price Target
2/2/2021Concert PharmaceuticalsTruistLower Price Target
2/2/2021Concert PharmaceuticalsHC WainwrightReiterated Rating
12/16/2020Concert PharmaceuticalsBerenberg BankInitiated Coverage
11/4/2020Concert PharmaceuticalsJMP SecuritiesInitiated Coverage
10/2/2020Concert PharmaceuticalsMizuhoReiterated Rating
3/30/2020Concert PharmaceuticalsJefferies Financial GroupInitiated Coverage
2/27/2020Concert PharmaceuticalsStifel NicolausDowngrade
1/22/2020Concert PharmaceuticalsSunTrust BanksReiterated Rating
9/30/2019Concert PharmaceuticalsJanney Montgomery ScottReiterated Rating
12/17/2020Medicenna TherapeuticsOppenheimerInitiated Coverage
8/24/2020Medicenna TherapeuticsBrookline Capital ManagementReiterated Rating
8/24/2020Medicenna TherapeuticsBloom BurtonReiterated Rating
10/1/2020Iterum TherapeuticsSVB LeerinkBoost Price Target
5/14/2020Iterum TherapeuticsNeedham & Company LLCReiterated Rating
1/21/2020Iterum TherapeuticsG.ResearchDowngrade
1/21/2020Iterum TherapeuticsGabelliDowngrade
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.